Most Read Articles
3 days ago
Tetanus toxoid 5 Lf, diphtheria toxoid 2 Lf, pertussis toxoid 2.5 mcg, filamentous haemagglutinin 5 mcg, fimbriae types 2 and 3 5 mcg, pertactin 3 mcg
Pearl Toh, 22 Oct 2020
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Jairia Dela Cruz, 3 days ago
The selective serotonin reuptake inhibitor escitalopram holds promise in the prevention of Alzheimer’s disease, reducing amyloid-β-42 levels in cerebrospinal fluid and brain tissue in older adults with normal cognitive function, according to recent evidence.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

Albendazole reverses IGF-1 lowering due to helminthic infections

15 Nov 2020

Helminthic infections decrease the levels of free insulin-like growth factor-1 (IGF-1), a marker of nutritional status in adults, a recent Indonesia study has found. Albendazole, an antihelminthic agent, counters this effect.

Through enzyme-linked immunosorbent assays, the researchers measured the levels of free IGF-1 and its major binding protein, IGFBP-3, in 1,604 participants. Measurements were collected before and after four rounds of treatment with 400-mg/day albendazole or matching placebo. Helminth infection was determined using microscopy or polymerase chain reaction (PCR).

After exclusions and randomization, 768 participants were given albendazole and 836 received placebo. The baseline percentage of patients with helminth infection was comparable between groups, both when microscopy (42.0 percent vs 44.2 percent) or PCR (54.7 percent vs 54.6 percent) were used.

In addition, serum levels of free IGF-1 were significantly lower among infected participants. This remained true even after adjusting for demographic factors, body mass index (BMI), fasting insulin concentration, and the inflammatory marker high-sensitivity C-reactive protein. However, the IGF-1 difference was only apparent when infections were determined using PCR, and not when microscopy was used.

After the intervention, both PCR and microscopy detected significant reductions in helminth infections. This was accompanied by a spike in free IGF-1. In the overall population, an IGF-1 increase of 0.031 ng/mL (95 percent confidence interval, 0.004–0.057; p=0.024) was detected, but this was not accompanied by a similar change in IFGBP-3 (p=0.968). The primary findings were unchanged when adjusting for BMI and fasting insulin.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
3 days ago
Tetanus toxoid 5 Lf, diphtheria toxoid 2 Lf, pertussis toxoid 2.5 mcg, filamentous haemagglutinin 5 mcg, fimbriae types 2 and 3 5 mcg, pertactin 3 mcg
Pearl Toh, 22 Oct 2020
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Jairia Dela Cruz, 3 days ago
The selective serotonin reuptake inhibitor escitalopram holds promise in the prevention of Alzheimer’s disease, reducing amyloid-β-42 levels in cerebrospinal fluid and brain tissue in older adults with normal cognitive function, according to recent evidence.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.